Cabenuva is ViiV Healthcare’s first long-acting injectable and combines the integrase strand transfer inhibitor (INSTI) cabotegravir, with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine.

Cabenuva was approved by Health Canada on 18 March 2020. It is the first and only once-monthly, complete long-acting regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral (ARV) regimen in those who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). 1

Cabenuva is currently under review by other global regulatory authorities.

[1] Cabenuva (cabotegravir/rilpivirine) Product Monograph Canada.

Prescribing information


Product Monograph for Cabenuva

Monographie de Cabenuva